AstraZeneca Makes $275 Million From COVID-19 Vaccine Sales In 3 months

US Trial Finds AstraZeneca 79 Percent Effective, No Blood Clot Risk
  • The results come at the end of a turbulent week after the European Union launched legal action against AstraZeneca over Covid-19 vaccine delivery delays

British pharmaceuticals giant AstraZeneca reported on Friday $275 million (227 million euros) in sales from its Covid vaccine in the first three months of the year.

It is the first time that the company discloses figures from sales of one of the world’s leading vaccines.

AstraZeneca’s Covid-19 jab was developed with the University of Oxford and has been key in Britain’s rapid vaccination drive. The company is selling it at cost price.

Read also: US Experts Recommend Resumption Of J&J Vaccine

However, public confidence in the jab has taken a blow over worries of links to very rare blood clots, and the company is in a legal fight with the EU over delivery shortfalls.


The company made the disclosure in an earnings statement showing that net profit doubled in the first quarter to $1.56 billion, compared with $780 million a year earlier.

Revenue jumped 15 percent — or 11 percent at constant exchange rates — to $7.32 billion in the reporting period.

Excluding the contribution from the Covid jab, revenues rose by 11 percent — or 7.0 percent at constant rates — to $7.045 billion.


Facebook Comments

Advertise or Publish a Story on EkoHot Blog:

Kindly contact us at Breaking stories should be sent to the above email and substantiated with pictorial evidence.

Citizen journalists will receive a token as data incentive.

Call or Whatsapp: 0803 561 7233, 0703 414 5611